Kamada Ltd. (NASDAQ:KMDA - Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.39 and traded as low as $5.31. Kamada shares last traded at $5.34, with a volume of 19,941 shares.
Analyst Upgrades and Downgrades
KMDA has been the subject of a number of recent research reports. StockNews.com downgraded shares of Kamada from a "strong-buy" rating to a "buy" rating in a report on Tuesday, August 27th. Stifel Nicolaus initiated coverage on shares of Kamada in a report on Wednesday, July 3rd. They set a "buy" rating and a $18.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $11.00 price target on shares of Kamada in a report on Thursday, August 15th.
View Our Latest Stock Analysis on KMDA
Kamada Price Performance
The company's 50-day moving average is $5.41 and its 200-day moving average is $5.39. The firm has a market capitalization of $305.51 million, a price-to-earnings ratio of 23.11 and a beta of 1.06.
Kamada (NASDAQ:KMDA - Get Free Report) last released its earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. Kamada had a net margin of 9.75% and a return on equity of 6.15%. The business had revenue of $42.47 million for the quarter, compared to analysts' expectations of $39.70 million. Sell-side analysts anticipate that Kamada Ltd. will post 0.26 earnings per share for the current year.
Institutional Investors Weigh In On Kamada
A hedge fund recently raised its stake in Kamada stock. Y.D. More Investments Ltd raised its holdings in shares of Kamada Ltd. (NASDAQ:KMDA - Free Report) by 1,956.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 726,161 shares of the biotechnology company's stock after buying an additional 690,842 shares during the period. Y.D. More Investments Ltd owned about 1.26% of Kamada worth $3,643,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 20.38% of the company's stock.
About Kamada
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Featured Articles
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
